Related Experiment Videos
Increased serum beta-2-microglobulin level in patients with inflammatory bowel disease
Bollettino Dell'Istituto Sieroterapico Milanese
|January 1, 1982
Summary
Elevated serum beta-2-microglobulin (B2m) levels are common in inflammatory bowel disease, particularly Crohn's disease. This finding suggests B2m may aid in diagnosing and monitoring this condition.
Area of Science:
- Immunology
- Gastroenterology
- Clinical Diagnostics
Background:
- Inflammatory bowel disease (IBD) encompasses Crohn's disease and idiopathic proctocolitis.
- Accurate diagnostic and monitoring tools for IBD are crucial for patient management.
Purpose of the Study:
- To investigate serum beta-2-microglobulin (B2m) levels in patients with inflammatory bowel disease.
- To assess the potential utility of B2m as a biomarker for Crohn's disease.
Main Methods:
- Serum samples were analyzed using a newly developed electroimmunoassay technique.
- B2m concentrations were measured in patients diagnosed with Crohn's disease and idiopathic proctocolitis.
Main Results:
- Increased serum B2m levels were observed in 66.7% of Crohn's disease patients (93 subjects).
- Elevated B2m was found in 56.0% of idiopathic proctocolitis patients (25 subjects).
- High B2m levels may correlate with increased lymphocyte activation in inflamed tissues.
Conclusions:
- Serum B2m shows potential as an adjunctive marker in the diagnostic evaluation of Crohn's disease.
- B2m monitoring could be valuable for assessing disease activity and treatment response in IBD.
- Elevated B2m concentrations likely reflect heightened immune system activity in IBD patients.